Interview with Michael Pehl, Managing Director, Celgene Germany
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Address: Kobelweg 95, 86156 Augsburg,Germany
Tel: +49 (0)800 7488100
Established in 1984, Dr. Reddy’s Laboratories (NYSE: RDY) is an emerging global pharmaceutical company. As a fully integrated pharmaceutical company, our purpose is to provide affordable and innovative medicines through our three core businesses: Pharmaceutical Services and Active Ingredients; Global Generics; and Proprietary Products.
Our products are marketed globally, with a focus on India, US, Europe and Russia. Dr. Reddy’s conducts NCE research in the areas of metabolic disorders, cardiovascular indications, anti-infectives and inflammation.
betapharm GmbH:
Founded in 1993 in Augsburg, betapharm generics (sells patent medicines) and is one of the leading generic companies in Germany. In March 2004 betapharm was sold to the British financial investor 3i. Since March 2006 betapharm belongs to the international pharmaceutical company Dr. Reddy’s Laboratories, headquartered in Hyderabad, India.
The product range of betapharm includes over 150 active ingredients in over 900 commercial forms and covers all major indications of the common cold to severe cardiovascular disease. In the case of prescription medicines focuses on the areas of cardiovascular, neurology and pain / palliative. The treatment of pain is also in the non-prescription drugs from betapharm in focus.
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
You have a wide experience in the pharmaceutical industry having worked for companies such as Amgen and Servier. What attracted you to Basilea? When I first considered moving to Basilea…
When we met Dr. Aleiotti in Italy, he said how important was Menarini´s acquisition of Berlin Chemie in the 1990s for the internationalization of the company in Eastern Europe and…
With a wide experience in other international pharmaceutical companies, what attracted you to come to Bausch&Lomb, the ophthalmology pharma company? Bausch&Lomb offered me a unique set of challenges and possibilities…
Gilead was founded in 1987 and only four years later it established itself in the German market. Since then the company has become internationally known for breakthroughs that resulted in…
See our Cookie Privacy Policy Here
